Barr To Pursue Generic Version of Neupogen Under Agreement With Pliva
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr agreement with Pliva marks the generic drug marketer's second move into generic biologics, with the company aiming to become an early leader in the field. Barr will be responsible for regulatory work to establish a pathway for approval of G-CSF.
You may also be interested in...
Barr Gains European Foothold Through $2.2 Bil. Pliva Acquisition
Pliva’s supervisory board accepts Barr’s bid despite several rivals vying for the Croatian generics firm.
Barr Gains European Foothold Through $2.2 Bil. Pliva Acquisition
Pliva’s supervisory board accepts Barr’s bid despite several rivals vying for the Croatian generics firm.
Generic Biologics Timing Depends On FDA Commissioner, Barr Says
The products could be on the market within three years if an FDA commissioner of former chief McClellan's "disposition" is confirmed, CEO Downey says. The process could take longer if the confirmed commissioner is more "reticent to change."